Fundamental Analysis of IMMURON LTD-SPON ADR(NASDAQ:IMRN) stock

Fundamental Rating

Taking everything into account, IMRN scores 3 out of 10 in our fundamental rating. IMRN was compared to 586 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for IMRN as it has an excellent financial health rating, but there are worries on the profitability. IMRN has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

IMRN had negative earnings in the past year.

In the past year IMRN has reported a negative cash flow from operations.

IMRN had negative earnings in each of the past 5 years.

In the past 5 years IMRN always reported negative operating cash flow.

1.2 Ratios

IMRN has a Return On Assets of -19.52%. This is amongst the best in the industry. IMRN outperforms 81.13% of its industry peers.

IMRN has a Return On Equity of -22.15%. This is amongst the best in the industry. IMRN outperforms 84.05% of its industry peers.

		Industry Rank	Sector Rank
ROA	-19.52%
ROE	-22.15%
ROIC	N/A

ROA(3y)-19.9%

ROA(5y)-32.26%

ROE(3y)-21.33%

ROE(5y)-35.84%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

With an excellent Gross Margin value of 80.87%, IMRN belongs to the best of the industry, outperforming 87.99% of the companies in the same industry.

IMRN's Gross Margin has improved in the last couple of years.

IMRN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	80.87%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y9.89%

GM growth 5Y1.69%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

IMRN does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for IMRN remains at a similar level compared to 1 year ago.

The number of shares outstanding for IMRN has been increased compared to 5 years ago.

The debt/assets ratio for IMRN is higher compared to a year ago.

2.2 Solvency

IMRN has an Altman-Z score of 0.76. This is a bad value and indicates that IMRN is not financially healthy and even has some risk of bankruptcy.

The Altman-Z score of IMRN (0.76) is better than 61.92% of its industry peers.

IMRN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	0.76

ROIC/WACCN/A

WACC8.9%

2.3 Liquidity

IMRN has a Current Ratio of 8.52. This indicates that IMRN is financially healthy and has no problem in meeting its short term obligations.

IMRN's Current ratio of 8.52 is fine compared to the rest of the industry. IMRN outperforms 71.01% of its industry peers.

IMRN has a Quick Ratio of 7.79. This indicates that IMRN is financially healthy and has no problem in meeting its short term obligations.

The Quick ratio of IMRN (7.79) is better than 68.61% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	8.52
Quick Ratio	7.79

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

IMRN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -28.51%.

IMRN shows a strong growth in Revenue. In the last year, the Revenue has grown by 219.95%.

IMRN shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -13.34% yearly.

EPS 1Y (TTM)-28.51%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q-4.84%

Revenue 1Y (TTM)219.95%

Revenue growth 3Y-10.51%

Revenue growth 5Y-13.34%

Revenue growth Q2Q303.59%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for IMRN. In the last year negative earnings were reported.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

IMRN does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

IMMURON LTD-SPON ADR

NASDAQ:IMRN (5/20/2024, 2:19:39 PM)

2.33

+0.01 (+0.43%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap13.27M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-19.52%
ROE	-22.15%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	80.87%
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.18

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	8.52
Quick Ratio	7.79
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)-28.51%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next YN/A

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)219.95%

Revenue growth 3Y-10.51%

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

IMMURON LTD-SPON ADR (IMRN)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens